Agendia
Board of Directors Appoints Jan Egberts, M.D., as CEO
Agendia, Inc., a leading
molecular diagnostic company, today announced the appointment of life science
industry veteran and Agendia board member Jan H. Egberts, M.D., as CEO. He
replaces David Macdonald, who has left the company to pursue other opportunities.
Dr. Egberts has more than
25 years of executive experience in the pharmaceutical and medical device
sectors. He served most recently as CEO of the specialty pharmaceutical company
OctoPlus (Euronext; OCTO), which was acquired in 2013 by India-based Dr. Reddy’s
Laboratories Ltd. Prior to OctoPlus, he held business development and general
management positions of increasing responsibility at McKinsey & Co., Merck,
Johnson & Johnson and Mölnlycke Health Care and served as CEO of Novadel
Pharmaceuticals, Inc. Dr. Egberts also served as Operating Partner/Senior
Advisor Healthcare for 3i, the private equity firm. He graduated from Erasmus
University Medical School in the Netherlands and pursued his clinical training
at Harvard Medical School. He obtained his MBA from Stanford after which he
worked as a management consultant at McKinsey & Co.
“I’m pleased to be able to
further serve Agendia’s growing number of physician customers, their patients
and my fellow shareholders,” Dr. Egberts said. “I’m firmly committed to leading
the company and laying the foundation for the next level of success, as we
expand the sales of MammaPrint, BluePrint and our other molecular tests, and as
we continue to bring the benefits of our tests to patients around the world.”
Dr. Egberts noted that
Agendia’s molecular diagnostic technology for breast cancer has recently been
featured in a number of prominent scientific studies, journal articles and
peer-reviewed presentations, including:
Publication of a large
multi-site study in the Annals of Surgical Oncology, validating the MammaPrint
and BluePrint tests’ ability to identify molecular subtypes and better guide
preoperative treatment
Presentation of the first
independent study to document how MammaPrint and BluePrint together eliminate
the uncertainty of “intermediate” results for risk of breast cancer recurrence,
an uncertainty that is inherent in competing technologies.
Progress in the I-SPY 2
clinical trial involving the US FDA, NIH, leading academic cancer centers and
pharmaceutical companies, for which MammaPrint was selected the biomarker of
choice.
“Having achieved these
recent milestones, Agendia is well positioned to continue its growth trajectory
and provide a highly accurate and actionable molecular diagnostics platform for
the oncology community and other stakeholders,” Dr Egberts said.
About
Agendia
Agendia is a privately
owned, leading molecular diagnostic company that develops and markets
FFPE-based genomic diagnostic products, which help support physicians with
their complex treatment decisions. Agendia’s breast cancer suite was developed
using an unbiased gene selection by analyzing the complete human genome. This
includes FDA-cleared MammaPrint as well as BluePrint, a molecular subtyping
assay that provides deeper insight leading to more clinically actionable
biology, and TargetPrint®, an ER/PR/HER2 expression assay. MammaPrint is the
only breast cancer recurrence assay back by peer-reviewed, prospective outcome
data. These tests can help physicians assess a patient’s individual risk for
metastasis, which patients may benefit from chemo, hormonal, or combination
therapy, and which patients may not require these treatments and can instead be
treated with other, less arduous and less costly methods.
In addition, Agendia has a
pipeline of other genomic products in development. The company collaborates
with pharmaceutical companies, leading cancer centers and academic groups to
develop companion diagnostic tests in the area of oncology and is a critical
partner in the I-SPY 2 and the MINDACT trials.
No comments:
Post a Comment